Saturday 17 October 2026
Export SNYRQ’s income statement to Excel — free account
Synergy CHC Corp.
SNYRQ Healthcare Medical Distribution
Synergy CHC Corp.’s revenue for fiscal 2025 (year ended December 2025) was $30.4 million, down 12.8% from fiscal 2024. In the quarter to March 2026, revenue fell 32.8%, EPS fell 330.0%, free cash flow fell 148.5% and total debt rose 7.08%, each against the same quarter a year earlier.
0.00
0.01
−100.00%
Follow SNYRQ
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 8.41 | 7.50 |
+8 more quarters Free account |
P/S ratio |
0.53 | 0.60 | 0.71 | 0.76 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.13) | 28.98 | (10.68) | (330.92) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.42 | 1.33 | 1.41 | 1.45 | |
EV/EBITDA |
0.00 | 0.00 | 6.52 | 6.94 | |
EV/Operating CF |
(10.33) | (15.67) | (7.36) | (10.74) | |
EV/FCF |
(10.33) | (15.67) | (7.36) | (10.74) | |
Quick Ratio |
0.24 | 0.72 | 3.79 | 2.12 | |
Current Ratio |
0.93 | 1.22 | 5.35 | 2.74 | |
Net Debt/EBITDA |
58.89 | (1.76) | 15.49 | 10.93 | |
Debt/Assets |
387.18% | 247.50% | 121.37% | 126.63% | |
Debt/Equity |
(0.98) | (1.09) | (3.04) | (2.02) | |
Asset Turnover |
2.51 | 2.29 | 2.11 | 2.18 | |
Operating CF/Net income |
0.80 | (0.04) | (18.43) | (0.05) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(0.28) | (8.57) | 1.10 | 0.77 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
82.01% | 145.68% | 54.52% | 56.32% | |
Intangible Assets out of Total Assets |
0.02 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
2.12% | 1.92% | 1.84% | 10.41% | |
Graham Net Nets |
(1.75) | (1.29) | (0.34) | (0.49) | |
Graham Number |
8.41 | 7.57 | 0.00 | 0.00 | |
Earnings Yield |
(108.53%) | (57.53%) | 11.89% | 13.33% | |
Free Cash Flow Yield |
(26.11%) | (14.29%) | (26.90%) | (17.93%) | |
Revenue per Share |
0.49 | 0.62 | 0.79 | 0.91 | |
Operating CF per Share |
(0.18) | 0.06 | (0.23) | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.18) | 0.06 | (0.23) | (0.01) | |
Cash per Share |
0.03 | 0.28 | 0.11 | 0.17 | |
Shareholders Equity per Share |
(2.25) | (2.38) | (0.82) | (1.39) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.25) | (2.38) | (0.82) | (1.39) | |
Free Cash Flow |
(2.04) | 0.62 | (2.31) | (0.08) | |
Working Capital |
(0.50) | 1.78 | 16.68 | 12.38 | |
Net Current Asset Value |
(25.52) | (23.28) | (8.44) | (12.60) | |
EV/EBIT |
0.00 | 0.00 | 7.86 | 8.19 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 3.97 | 4.25 | |
| Other line items | |||||
Average Receivables |
5.94 | 7.45 | 10.96 | 10.61 | |
Average Payables |
3.57 | 5.79 | 4.33 | 5.07 | |
Average Inventory |
2.86 | 2.73 | 2.03 | 2.14 | |
Average Assets |
11.06 | 13.25 | 16.43 | 15.48 | |
Average Common Equity |
(20.52) | (19.88) | (16.71) | (19.13) |
Columns are period end dates